Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,611 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).
Cohen Stuart JW, Schuurman R, Burger DM, Koopmans PP, Sprenger HG, Juttmann JR, Richter C, Meenhorst PL, Hoetelmans RM, Kroon FP, Bravenboer B, Hamann D, Boucher CA, Borleffs JC. Cohen Stuart JW, et al. Among authors: richter c. AIDS. 1999 May 7;13(7):F53-8. doi: 10.1097/00002030-199905070-00001. AIDS. 1999. PMID: 10357371 Clinical Trial.
The ADAM study continued: maintenance therapy after 50 weeks of induction therapy.
Reijers MH, Weverling GJ, Jurriaans S, Roos MT, Wit FW, Weigel HM, Ten Kate RW, Mulder JW, Richter C, Ter Hofstede HJ, Sprenger H, Hoetelmans RM, Schuitemaker H, Lange JM. Reijers MH, et al. Among authors: richter c. AIDS. 2001 Jan 5;15(1):129-31. doi: 10.1097/00002030-200101050-00022. AIDS. 2001. PMID: 11192858 Clinical Trial. No abstract available.
Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
Lowe SH, Wensing AM, Hassink EA, ten Kate RW, Richter C, Schreij G, Koopmans PP, Juttmann JR, van der Tweel I, Lange JM, Borleffs JC. Lowe SH, et al. Among authors: richter c. HIV Clin Trials. 2005 Sep-Oct;6(5):235-45. doi: 10.1310/A686-M37Y-J2PT-E9GJ. HIV Clin Trials. 2005. PMID: 16306030 Clinical Trial.
Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism.
Burger D, van der Heiden I, la Porte C, van der Ende M, Groeneveld P, Richter C, Koopmans P, Kroon F, Sprenger H, Lindemans J, Schenk P, van Schaik R. Burger D, et al. Among authors: richter c. Br J Clin Pharmacol. 2006 Feb;61(2):148-54. doi: 10.1111/j.1365-2125.2005.02536.x. Br J Clin Pharmacol. 2006. PMID: 16433869 Free PMC article.
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.
D:A:D Study Group; Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD. D:A:D Study Group, et al. Lancet. 2008 Apr 26;371(9622):1417-26. doi: 10.1016/S0140-6736(08)60423-7. Epub 2008 Apr 2. Lancet. 2008. PMID: 18387667 Free PMC article.
Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction.
Data Collection on Adverse Events of Anti-HIV Drugs Study Group; Sabin CA, d'Arminio Monforte A, Friis-Moller N, Weber R, El-Sadr WM, Reiss P, Kirk O, Mercie P, Law MG, De Wit S, Pradier C, Phillips AN, Lundgren JD. Data Collection on Adverse Events of Anti-HIV Drugs Study Group, et al. Clin Infect Dis. 2008 Apr 1;46(7):1101-10. doi: 10.1086/528862. Clin Infect Dis. 2008. PMID: 18461712 Free PMC article.
1,611 results